Skip to main content

Drug Interactions between Adbry and cholera vaccine, live

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

cholera vaccine, live tralokinumab

Applies to: cholera vaccine, live and Adbry (tralokinumab)

GENERALLY AVOID: The administration of live, attenuated viral or bacterial vaccines during therapy with the interleukin-13 antagonists tralokinumab or lebrikizumab may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. This interaction may also apply to oncolytic cancer immunotherapy agents, such as BCG, talimogene laherparepvec, and nadofaragene firadenovec. However, data evaluating the impact of these drugs on the safety and effectiveness of these vaccines or oncolytic cancer immunotherapy agents is not available.

MANAGEMENT: The manufacturers of tralokinumab and lebrikizumab recommend that the use of live, attenuated virus or bacterial vaccines be avoided during treatment with these drugs. Administration of all age-appropriate vaccines is recommended to be completed prior to initiation of either tralokinumab or lebrikizumab, and in accordance with current immunization guidelines. Until further information is available, concomitant use of oncolytic cancer immunotherapy agents such as BCG, talimogene laherparapvec, and nadofaragene firadenovec should also generally be avoided.

References (2)
  1. (2024) "Product Information. Ebglyss Pre-filled Pen (lebrikizumab)." Eli Lilly Canada Inc
  2. (2024) "Product Information. Ebglyss Prefilled Syringe (lebrikizumab)." Lilly, Eli and Company

Drug and food interactions

Moderate

cholera vaccine, live food

Applies to: cholera vaccine, live

ADJUST DOSING INTERVAL: Coadministration of oral cholera vaccine with food or an oral beverage may impair its efficacy. The formulations of both the inactivated and live, attenuated oral cholera vaccines (Dukoral and Vaxchora, respectively) are acid-labile, and must be administered with a buffer. According to the manufacturer, eating and drinking may interfere with the protective effect of the buffer. However, clinical data are not available.

MANAGEMENT: It is recommended that patients avoid eating or drinking for 60 minutes before and after administration of either Dukoral or Vaxchora oral cholera vaccines.

References (4)
  1. (2023) "Product Information. Vaxchora (cholera vaccine, live)." Patientric Ltd
  2. (2022) "Product Information. Dukoral (cholera vaccine, inactivated)." Valneva Sweden AB
  3. (2023) "Product Information. Dukoral (cholera vaccine)." Valneva UK Ltd
  4. (2024) "Product Information. Vaxchora (cholera vaccine, live)." Emergent Travel Health, Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer